Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: L01CD04

Cabazitaxel Accord(cabazitaxel)

Prostatic Neoplasms, Castration-Resistant

Marketing Authorisation Holder: Accord Healthcare S.L.U.

EMA Authorisation: 28/08/2020

INN: cabazitaxel

Indication

Treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Cabazitaxel Accord — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.